Spero Therapeutics (SPRO) Earnings Date and Reports 2024

1 day ago · Get the Latest News and Ratings for SPRO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Spero Therapeutics (NASDAQ:SPRO) …

CouponFollow Extension

$0.33
OFF

What Date Does Spero Therapeutics's (SPRO) Report Earnings

6 days from now

Report Date Period Ending Zacks Consensus Estimate Earnings ESP; 11/11/2024 ... Spero Therapeutics (SPRO) reported earnings of -$0.33 per share, beating the Zacks Consensus …

zacks.com

$7.67
OFF

What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 …

6 days from now

Nov 13, 2024 · Spero Therapeutics Inc (NASDAQ:SPRO) is set to release its Q3 2024 earnings on Nov 14, 2024. The consensus estimate for Q3 2024 revenue is $7.67 million, and the …

yahoo.com

47%
OFF

Spero Therapeutics Third Quarter 2024 Earnings: Beats Expectations

6 days from now

5 days ago · Spero Therapeutics (NASDAQ:SPRO) Third Quarter 2024 ResultsKey Financial Results. Revenue: US$13.5m (down 47% from 3Q 2023). Net loss: US$17.1m (loss widened …

yahoo.com

48%
OFF

Spero Therapeutics Earnings Dates, Reports, Calls 2014-2024 …

6 days from now

On SPRO's earnings call on Invalid Date, . Spero Therapeutics (NASDAQ: SPRO) reported Q2 2024 earnings per share (EPS) of -$0.33, up 43.48% year over year. Total SPRO earnings for …

wallstreetzen.com

$1.59
OFF

FATE Presents Encourgaing Data From Lupus Study, Stock Gains

6 days from now

4 days ago · In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.31. Estimates for 2025 loss per share have narrowed from $1.54 to …

zacks.com

$1.59
OFF

JAZZ Secures FDA Approval For Ziihera In Biliary Tract Cancer

6 days from now

2 days ago · In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.31. Estimates for 2025 loss per share have narrowed from $1.54 to …

zacks.com

$0.37
OFF

Cara Therapeutics (CARA) Earnings Date And Reports 2024

6 days from now

Nov 11, 2024 · Cara Therapeutics announced Q2 2024 earnings on August 14, 2024, reporting an EPS of -$0.37, which missed analysts' consensus estimates of -$0.27 by $0.10. Quarterly …

marketbeat.com

60%
OFF

Corcept Shares Rise More Than 60% In Three Months: Here's Why

6 days from now

1 day ago · In the past 60 days, estimates for Spero Therapeutics’ 2024 loss per share have narrowed from $1.59 to $1.13. Loss per share estimates for 2025 have narrowed from $1.54 to …

zacks.com

FAQs about Spero Therapeutics (SPRO) Earnings Date and Reports 2024 Coupon?

How did Spero Therapeutics Inc's (Spro) earnings compare to analysts' expectations?

In the previous quarter of June 30, 2024, Spero Therapeutics Inc's (NASDAQ:SPRO) actual revenue was $10.2 million, which beat analysts' revenue expectations of $3.27 million by 212.12%. Spero Therapeutics Inc's (NASDAQ:SPRO) actual earnings were -$0.33 per share, which beat analysts' earnings expectations of -$0.38 per share by 13.16%. ...

How did Spero Therapeutics Inc (Spro) perform in one day?

Spero Therapeutics Inc's (NASDAQ:SPRO) actual earnings were -$0.33 per share, which beat analysts' earnings expectations of -$0.38 per share by 13.16%. After releasing the results, Spero Therapeutics Inc (NASDAQ:SPRO) was down by -5.22% in one day. ...

What is the target price for Spero Therapeutics Inc (Spro)?

After releasing the results, Spero Therapeutics Inc (NASDAQ:SPRO) was down by -5.22% in one day. Based on the one-year price targets offered by 2 analysts, the average target price for Spero Therapeutics Inc (NASDAQ:SPRO) is $5 with a high estimate of $5 and a low estimate of $5. ...

Who is Spero Therapeutics?

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and MDR bacterial infections with high unmet need. For more information, visit www.sperotherapeutics.com ...

Should you buy Spero Therapeutics (Spro) stock?

Currently, the analyst consensus on Spero Therapeutics is a Moderate Buy with an average price target of $5.00. SPRO market cap is currently $64.33M and has a P/E ratio of 14.86. Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. ...

Why did Spero Therapeutics suspend its spr720 development activities?

In its latest earnings report, Spero Therapeutics highlighted the suspension of its SPR720 development activities due to insufficient efficacy in a Phase 2a study and potential safety concerns. ...